Clinical trials: Schizophrenia and Disorders With Psychotic Features
Schizophrenia
A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia
This is a study designed to evaluate the efficacy and safety of lurasidone in acutely psychotic patients with chronic schizophrenia and to confirm the non-inferiority of lurasidone relative to quetiapine XR.
- Trial name
- NCT03465787
- Testing
- Lurasidone HCL 160 mg, Quetiapine XR 600 mg
- Where
- South Korea
- Volunteers
- 210 people
- Sponsor
- Bukwang Pharmaceutical
Schizophrenia
Electroencephalogram (EEG) and Electroconvulsive Therapy(ECT) Response in Schizophrenia
This study is designed to find quantitative Electroencephalogram(qEEG) biomarkers to predict Electroconvulsive Therapy(ECT) Response in Schizophrenia
- Trial name
- NCT04220099
- Testing
- Electroconvulsive therapy(ECT)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia
Nicotinic Receptors and Schizophrenia
The study determines if a new preparation of a drug designed to treat schizophrenia is more slowly released into the body.
- Trial name
- NCT00952393
- Testing
- Pharmacokinetic
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Schizophrenia
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
The purpose of the trial was to evaluate the efficacy, safety, and tolerability of an intramuscular depot formulation of aripiprazole as maintenance treatment in patients with schizophrenia.
- Trial name
- ASPIRE (NCT00705783)
- Testing
- Aripiprazole depot
- Where
- 110 sites in United States, Argentina and 10 more
- Volunteers
- 843 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Study of SPG302 in Adults With Schizophrenia
This Phase 2 study described herein will evaluate the safety, efficacy, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia.
- Trial name
- NCT06442462
- Testing
- SPG302
- Where
- 3 sites in United States, Australia
- Volunteers
- 32 people
- Sponsor
- Spinogenix
Psychotic Disorders, Mood Disorders
A Preventive Behavioral Intervention for Young Adults With Psychotic Experiences
This is a randomized controlled trial testing the efficacy of Resilience Training in college students with elevated transdiagnostic risk for developing a serious mental illness.
- Conditions
- Psychotic Disorders, Mood Disorders, Anxiety Disorders
- Trial name
- NCT06929442
- Testing
- Resilience Training (RT), Life Skills Training (LST)
- Where
- United States
- Volunteers
- 192 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia
A Study of the Potential Effects of Trimethoprim on the Pharmacokinetics of ER OROS Paliperidone
The purpose of this study is to evaluate the effects of an organic cation transporter inhibitor, trimethoprim, on the pharmacokinetics of orally administered ER OROS paliperidone and to assess the safety and tolerability of the…
- Trial name
- NCT00892541
- Testing
- ER OROS paliperidone
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
SB-773812 Administered In Adults With Schizophrenia
This is a two part study designed to evaluate the safety and efficacy of SB-773812 in the treatment of acute schizophrenia. Subjects with acute schizophrenia will be randomized in an adaptive design study to receive placebo…
- Trial name
- NCT00259870
- Testing
- SB-773812, Olanzapine
- Where
- 45 sites in United States, Belgium and 5 more
- Volunteers
- 338 people
- Sponsor
- GlaxoSmithKline
Schizophrenia
Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia
The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with schizophrenia.
- Trial name
- NCT00711269
- Testing
- SM-13496 (lurasidone HCl), Risperidone
- Where
- 3 sites in Japan, South Korea and 1 more
- Volunteers
- 460 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Schizophrenia, Chronic Illness
Implementing Effective, Collaborative Care for Schizophrenia (EQUIP-2)
This project evaluates the implementation and effectiveness of a care model to improve treatment for schizophrenia within the context of diverse VA practices and priorities.
- Conditions
- Schizophrenia, Chronic Illness, Weight Gain, Psychotic Disorder
- Trial name
- EQUIP-2 (NCT00137280)
- Testing
- Collaborative Chronic Illness Care Model
- Where
- 8 sites in United States
- Volunteers
- 1,067 people
- Sponsor
- VA Office of Research and Development
Dyskinesia, Drug-Induced
Movement Disorders Caused by Antipsychotic Drugs in Older Patients
This study will assess the risk of experiencing tardive dyskinesia and other movement disturbances associated with three atypical antipsychotic drugs among middle-aged and elderly psychiatric patients.
- Trial name
- NCT00255879
- Testing
- Quetiapine, Risperidone, Olanzapine
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- University of California, San Diego
Schizophrenia, Schizoaffective Disorder
High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone
The purpose of this study is to look at two doses of long-acting injectable risperidone (Risperdal Consta). The study will use a usual dose of Risperdal Consta (50 mg given every two weeks) or a higher dose (75 mg-100 mg given…
- Trial name
- NCT00539071
- Testing
- long-acting injectable risperidone, long acting injectable risperidone, Conventional Dose Group, long acting injectable risperidone, High Dose Group
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Northwestern University
Psychotic Disorders, Schizophrenia
The Topical Niacin Skin Flush Test in First Episode Psychosis
The purpose of this study is to gather normative data from healthy adults and to determine a sensitive and specific cut-off value for responders and non-responders to the Niacin Skin Flush Test in a sample of first episode…
- Trial name
- NCT01324297
- Testing
- skin test
- Where
- Canada
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- Nova Scotia Health Authority
Psychosis, Schizophrenia
VR Therapy for Psychosis Negative Symptoms (V-NeST)
Background: Negative symptoms are typically observed in people with schizophrenia and indicate a loss or reduction of a normal function (e.g. reduced motivation and affect display).
- Trial name
- V-NeST (NCT03995420)
- Testing
- Virtual Reality Therapy (V-NeST), Treatment as Usual
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Institute of Psychiatry, London
Schizophrenia
Parallel Effects of Schizophrenia and N-methyl-D-aspartate (NMDA) Antagonism
This study investigates the common features of electrophysiological measures in schizophrenia and effects of NMDA antagonist ketamine in healthy volunteers.
- Trial name
- NCT02675530
- Testing
- ketamine
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Yale University
Schizophrenia
Study of add-on Ramelteon Therapy on Sleep and Circadian Rhythm Disruption in Patients With Schizophrenia
The proposed study has been planned to evaluate the effect of add-on ramelteon on sleep pattern/quality and circadian rhythm disruption in patients with schizophrenia.
- Trial name
- NCT03075657
- Testing
- Risperidone, Risperidone and Ramelteon, Haloperidol
- Where
- India
- Volunteers
- 120 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Smoking Cessation, Schizophenia Disorder
Effects of Smoking on Network Connectivity in Patients With Schizophrenia Symptoms in Scz Patients
The prevalence of smoking among people with schizophrenia (SCZ) is substantially higher at 54% to 90% (McClave et al., 2010). About half of all deaths amongst people with scz are attributed to smoking-related diseases and cancer…
- Trial name
- ACT (NCT07441928)
- Testing
- Acceptance and Commitment Therapy (ACT-SC), 5A model (Ask, Assess, Advice, Assist & Arrange) smoking cessation intervention (5A-SC)
- Where
- 5 sites in Hong Kong
- Volunteers
- 90 people
- Sponsor
- The Hong Kong Polytechnic University
Schizophrenia
Biological Evaluation of Dietary Supplement Liposomal Glutathione
Low levels of antioxidant molecules such as glutathione have been found in people with a diagnosis of schizophrenia. However, oral glutathione is not well absorbed because the compound is mostly broken down in the…
- Trial name
- NCT01967667
- Testing
- Liposomal glutathione
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia
Evaluation Study of New Compounds With Potential Use in Schizophrenia
Different compounds that might modify the glucose regulation in the central nervous system will be evaluated in healthy volunteers.
- Trial name
- EICAS (NCT00916201)
- Testing
- URB597, intranasal Insulin, Cannabidiol CR
- Where
- Germany
- Volunteers
- healthy volunteers welcome
- Sponsor
- Central Institute of Mental Health, Mannheim
Schizophrenia
Clinical Intervention on Cognitive Impairment of Schizophrenia With Metabolic Syndrome
This is a single-center, randomized, parallel-control study conducted in schizophrenic inpatients with metabolic syndrome who have been conducted with olanzapine.
- Trial name
- NCT04518319
- Testing
- Omega-3 polyunsaturated fatty acids, Xbox aerobic exercise, transcranial direct current stimulation,tDCS
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Mental Health Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.